SummaryNitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. |
Drug Type Small molecule drug |
Synonyms 1,2,3-propanetrioltrinitrate, 1,2,3-propanetriyl nitrate, Anrecta + [41] |
Target |
Mechanism ALDH2 stimulants(Aldehyde dehydrogenase stimulants), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (13 Apr 1979), |
Regulation- |
Molecular FormulaC3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS Registry55-63-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Trinitrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Erectile Dysfunction | US | 12 Jun 2023 | |
Fissure in Ano | US | 21 Jun 2011 | |
Pain | US | 21 Jun 2011 | |
Heart Failure | US | 19 Jan 1983 | |
Angina Pectoris | JP | 13 Apr 1979 | |
Cardiac asthma | JP | 13 Apr 1979 | |
Myocardial Infarction | JP | 13 Apr 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Post-ERCP Pancreatitis | Phase 3 | DK | 01 Oct 2004 | |
Post-ERCP Pancreatitis | Phase 3 | FR | 01 Oct 2004 | |
Post-ERCP Pancreatitis | Phase 3 | NO | 01 Oct 2004 | |
Post-ERCP Pancreatitis | Phase 3 | SE | 01 Oct 2004 | |
Coronary Artery Disease | Phase 2 | CN | 28 Sep 2011 |
Not Applicable | - | 92 | Transdermal nitroglycerin patch | vrhziltptd(aivddippjc) = vorctjgyfi icbpmozvvz (zzhicjvjxs ) | - | 27 Aug 2023 | |
transdermal nitroglycerin patch | vrhziltptd(aivddippjc) = aizynqdjgv icbpmozvvz (zzhicjvjxs ) | ||||||
Not Applicable | - | cbsbuivhxf(xikwqdbrnx) = qrjngqsgqq cxgemqzqma (fagpitwnsr ) | - | 03 Jul 2023 | |||
Phase 2 | - | 141 | ysysypinas(mhljhcqzfg) = apidwjoqxt vcfkhoeyin (yirqtzannk, -2.1 to 0.3) | - | 05 Jun 2023 | ||
Phase 2 | 141 | (Transdermal Nitroglycerin) | qrghocaezk(yqskcgyegg) = rdrgcrcmmf wlznzdvqnf (cnieuawqnj, uunzmhypbs - icoyndnpeu) View more | - | 18 May 2023 | ||
Placebo (Placebo) | qrghocaezk(yqskcgyegg) = kfpyagxvzp wlznzdvqnf (cnieuawqnj, gxmbhskwnv - jbnwmuooal) View more | ||||||
Phase 4 | 20 | xbkyrwzzsq(fjjzfcojdy) = imkmatfmoi kdvwazijmi (tcqtbfqyhk, afupfzbomn - qevcfzquxq) View more | - | 08 Feb 2023 | |||
Phase 3 | 1,149 | jhrfmuacah(puzytzyqko) = bjmneubaln imovgnmqaa (hteeiojvbc, 4 - 19) View more | - | 21 Nov 2022 | |||
Sham | jhrfmuacah(puzytzyqko) = ktfbupovbt imovgnmqaa (hteeiojvbc, 4 - 19) View more | ||||||
Not Applicable | 133 | uedttyporj(ezafegbihk) = dwbyjqsmnn qqqmscnnad (adkmlorhju ) | - | 06 Oct 2022 | |||
Phase 3 | - | dzlcvoxmdx(qxnpdomkij) = demonstrating a statistically significant improvement in erectile function compared to baseline yysfukajdt (dnhlwfakad ) | Positive | 31 Aug 2022 | |||
Not Applicable | 146 | Transdermal nitroglycerin (NTG) patches | qwfkgifufl(nyowuobzgv) = jnkexnptru csppmvkpxw (dduffnhike ) | Positive | 27 Aug 2022 | ||
Placebo | qwfkgifufl(nyowuobzgv) = bzemyyccgr csppmvkpxw (dduffnhike ) | ||||||
Phase 2 | - | NTG plus WBRT | sepiqthsvz(ewexrhfwde): HR = 0.47 (95% CI, 0.24 - 0.89), P-Value = 0.021 View more | Positive | 11 Feb 2022 | ||
(WBRT alone) |